A Director at Eagle Pharmaceuticals Inc is Exercising Options

By Carrie Williams

Today it was reported that a Director at Eagle Pharmaceuticals Inc (EGRXResearch Report), Steven Ratoff, exercised options to buy 2,340 EGRX shares at $4.04 a share, for a total transaction value of $9,453. The options were close to expired and Steven Ratoff retained stocks.

Following this transaction Steven Ratoff’s holding in the company was increased by 14.94% to a total of $877.7K.

See today’s analyst top recommended stocks >>

Based on Eagle Pharmaceuticals Inc’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $56.05 million and quarterly net profit of $12.59 million. In comparison, last year the company earned revenue of $46.79 million and had a net profit of $9.08 million. EGRX’s market cap is $678.3M and the company has a P/E ratio of 23.18. Currently, Eagle Pharmaceuticals Inc has an average volume of 183.9K.

Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $54.67, reflecting a 14.0% upside.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban; ryanodex; docetaxel injection, non-alcohol formulation; and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.